Medpace (NASDAQ:MEDP) Director Sells $3,830,453.20 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Robert Kraft sold 6,472 shares of the stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $591.85, for a total transaction of $3,830,453.20. Following the transaction, the director directly owned 833 shares of the company’s stock, valued at approximately $493,011.05. This trade represents a 88.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Medpace Trading Up 0.8%

Medpace stock traded up $4.42 during trading on Tuesday, hitting $590.18. The company had a trading volume of 219,107 shares, compared to its average volume of 415,017. The stock has a market cap of $16.62 billion, a price-to-earnings ratio of 41.27, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $625.00. The company’s 50 day simple moving average is $541.26 and its 200-day simple moving average is $426.46.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. During the same period last year, the business posted $3.01 earnings per share. The company’s quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

MEDP has been the topic of a number of recent research reports. Zacks Research upgraded shares of Medpace from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 27th. William Blair restated a “market perform” rating on shares of Medpace in a report on Wednesday, July 23rd. Truist Financial set a $555.00 target price on shares of Medpace in a report on Monday, October 27th. Rothschild & Co Redburn cut shares of Medpace from a “buy” rating to a “neutral” rating and raised their price target for the company from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Finally, Jefferies Financial Group upped their price objective on Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a research report on Tuesday, September 9th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have assigned a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $487.18.

Hedge Funds Weigh In On Medpace

Several large investors have recently bought and sold shares of the business. Mawer Investment Management Ltd. purchased a new stake in Medpace during the 1st quarter worth about $212,131,000. AQR Capital Management LLC lifted its stake in Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Vulcan Value Partners LLC lifted its stake in Medpace by 221.6% during the first quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company’s stock worth $99,159,000 after purchasing an additional 224,578 shares during the last quarter. Norges Bank acquired a new position in Medpace in the second quarter valued at approximately $66,597,000. Finally, Arrowstreet Capital Limited Partnership increased its stake in Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after purchasing an additional 211,411 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.